Covid19 Clinical Trial
— PRO-CARFOfficial title:
Prone Positioning in Non-intubated Patients With Severe COVID-19: a Randomized Controlled Trial
NCT number | NCT04477655 |
Other study ID # | 048/20 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 3, 2020 |
Est. completion date | January 26, 2021 |
Verified date | April 2021 |
Source | Hospital Civil de Guadalajara |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Besides protective ventilation with low tidal volumes, prone positioning is a proven intervention to decrease mortality in mechanically ventilated patients with moderate-severe acute respiratory distress syndrome. However, the evidence of this strategy in awake non-intubated patients is scarce. The investigators will perform a randomized controlled trial to define if prone positioning can reduce the requirement of mechanical ventilation.
Status | Completed |
Enrollment | 430 |
Est. completion date | January 26, 2021 |
Est. primary completion date | January 26, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Adult patients with confirmed COVID-19, and requirement of a fraction of inspired oxygen (FiO2) =30% through high-flow nasal cannula (HFNC) to maintain a capillary saturation of =90% Exclusion Criteria: - Less than 18 years-old - Pregnancy - Patients with immediate need of invasive mechanical ventilation - Contraindications for prone positioning therapy - Do-not-resuscitate or do-not-intubate order - Refusal of the patient or decision maker to enroll in the study |
Country | Name | City | State |
---|---|---|---|
Mexico | Hospital Civil Fray Antonio Alcalde | Guadalajara | Jalisco |
Mexico | Hospital General de Occidente | Guadalajara | Jalisco |
Lead Sponsor | Collaborator |
---|---|
Hospital Civil de Guadalajara |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intubation rate | 28 days | ||
Secondary | Total hours of prone position at day | 28 days | ||
Secondary | Total number of prone sessions at day | 28 days | ||
Secondary | Hours of the longest prone session each day | 28 days | ||
Secondary | Change in oxygenation 1-hour after first prone session | 1 hour | ||
Secondary | Change in the ROX-index 1-hour after first prone session | The change in the Ratio of Oxygen saturation to respiratory rate (ROX-index) | 1 hour | |
Secondary | Total days of prone positioning therapy | 28 days | ||
Secondary | Adverse effects of prone positioning therapy | 28 days | ||
Secondary | Mechanical ventilation days | 28 days | ||
Secondary | Intensive care unit length of stay | 28 days | ||
Secondary | Hospital length of stay | 28 days | ||
Secondary | Hospital mortality | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |